Chinthanie Ramasundarahettige
A5075758795- Atrial Fibrillation Management and Outcomes
- Cardiac Arrhythmias and Treatments
- Health Systems, Economic Evaluations, Quality of Life
- Diabetes Treatment and Management
- Diabetes Management and Research
- Global Public Health Policies and Epidemiology
- Antiplatelet Therapy and Cardiovascular Diseases
- Global Cancer Incidence and Screening
- Peripheral Artery Disease Management
- Venous Thromboembolism Diagnosis and Management
- Pharmaceutical Economics and Policy
- Heart Failure Treatment and Management
- Smoking Behavior and Cessation
- Cardiovascular Function and Risk Factors
- Nutritional Studies and Diet
- Cerebrovascular and Carotid Artery Diseases
- Cardiovascular Disease and Adiposity
- Blood Pressure and Hypertension Studies
- Cervical Cancer and HPV Research
- Climate Change and Health Impacts
- Health disparities and outcomes
- Cardiac, Anesthesia and Surgical Outcomes
- Fatty Acid Research and Health
- Lipoproteins and Cardiovascular Health
- Cardiac Imaging and Diagnostics
Hamilton Health Sciences
2019-2025
McMaster University
2016-2025
Population Health Research Institute
2017-2025
Impact
2022
McGill University
2021
Health Sciences Centre
2019
Bayer (France)
2018
Pfizer (United Kingdom)
2018
The University of Sydney
2017
St. Michael's Hospital
2012-2014
Extrapolation from studies in the 1980s suggests that smoking causes 25% of deaths among women and men 35 to 69 years age United States. Nationally representative measurements current risks benefits cessation at various ages are unavailable.
Four glucagon-like peptide-1 (GLP-1) receptor agonists that are structurally similar to human GLP-1 have been shown reduce the risk of adverse cardiovascular events among persons with type 2 diabetes. The effect an exendin-based agonist, efpeglenatide, on and renal outcomes in patients diabetes who also at high for is uncertain.
Socioeconomic status is associated with differences in risk factors for cardiovascular disease incidence and outcomes, including mortality. However, it unclear whether the associations between common measures of socioeconomic status-wealth education-differ among high-income, middle-income, low-income countries, and, if so, why these exist. We explored association education household wealth mortality to assess which marker stronger predictor examined any by parallel factor levels or...
BackgroundHypertension is considered the most important risk factor for cardiovascular diseases, but its control poor worldwide. We aimed to assess availability and affordability of blood pressure-lowering medicines, association with use these medicines pressure in countries at varying levels economic development.MethodsWe analysed availability, costs, data recorded from 626 communities 20 participating Prospective Urban Rural Epidemiological (PURE) study. Medicines were available if they...
Testing of factor Xa inhibitors for the prevention cardiovascular events in patients with rheumatic heart disease-associated atrial fibrillation has been limited. We enrolled and echocardiographically documented disease who had any following: a CHA2DS2VASc score at least 2 (on scale from 0 to 9, higher scores indicating risk stroke), mitral-valve area no more than cm2, left spontaneous echo contrast, or thrombus. Patients were randomly assigned receive standard doses rivaroxaban...
Angiotensin-converting enzyme 2 (ACE2) is an endogenous counter-regulator of the renin-angiotensin hormonal cascade. We assessed whether plasma ACE2 concentrations were associated with greater risk death or cardiovascular disease events.We used data from Prospective Urban Rural Epidemiology (PURE) prospective study to conduct a case-cohort analysis within subset PURE participants (from 14 countries across five continents: Africa, Asia, Europe, North America, and South America). measured...
Both sodium-glucose cotransporter-2 (SGLT2) inhibitors and glucagon-like peptide-1 receptor agonists reduce cardiovascular events among patients with type 2 diabetes. However, no outcome trial has evaluated the long-term effects of their combined use. The AMPLITUDE-O (Effect Efpeglenatide on Cardiovascular Outcomes) reported that once-weekly injections efpeglenatide (versus placebo) reduced major adverse (MACEs); MACEs, coronary revascularization, or unstable angina hospitalization (expanded...
<h3>Importance</h3> Stress may increase the risk of cardiovascular disease (CVD). Most studies on stress and CVD have been conducted in high-income Western countries, but whether is associated with other settings has less well studied. <h3>Objective</h3> To investigate association a composite measure psychosocial development events mortality large prospective study involving populations from 21 high-, middle-, low-income countries across 5 continents. <h3>Design, Setting, Participants</h3>...
To directly estimate how much smoking contributes to cause-specific mortality in Bangladesh.A case-control study was conducted with surveillance data from Matlab, a rural subdistrict. Cases (n = 2213) and controls 261) were men aged 25 69 years who had died between 2003 2010 smoking-related non-smoking-related causes, respectively. Cause-specific odds ratios (ORs) calculated for "ever-smokers" versus "never-smokers", adjustment education, tobacco chewing status age. Smoking-attributable...
Background: In the AMPLITUDE-O (Effect of Efpeglenatide on Cardiovascular Outcomes) cardiovascular outcomes trial, adding either 4 mg or 6 weekly glucagon-like peptide-1 receptor agonist efpeglenatide to usual care reduced major adverse events (MACE) in people with type 2 diabetes at high risk. Whether these benefits are dose related remains uncertain. Methods: Participants were randomly assigned a 1:1:1 ratio placebo, efpeglenatide. The effect versus placebo and MACE (a nonfatal myocardial...
Despite the growing utility of cardiovascular magnetic resonance (CMR) for cardiac morphology and function, sex age-specific normal reference values derived from large, multi-ethnic data sets are lacking. Furthermore, most available studies use a simplified tracing methodology. Using large cohort participants without history disease (CVD) or risk factors Canadian Alliance Healthy Heart Minds, we sought to establish robust set ventricular atrial parameters using an anatomically correct...
LAAOS III (Left Atrial Appendage Occlusion Study III) showed that left atrial appendage (LAA) occlusion reduces the risk of ischemic stroke or systemic embolism in patients with fibrillation undergoing cardiac surgery. This article examines effect LAA on reduction according to variation use oral anticoagulant (OAC) therapy.Information regarding OAC was collected at every follow-up visit. Adjusted proportional hazards modeling, including using landmarks hospital discharge, 1 and 2 years after...
Background: Atrial fibrillation (AF) is often detected for the first time in patients who are hospitalized another reason. Long-term risks AF recurrence these unclear. Objective: To estimate risk with new-onset during a hospitalization noncardiac surgery or medical illness compared matched population without AF. Design: Matched cohort study. (ClinicalTrials.gov: NCT03221777) Setting: Three academic hospitals Hamilton, Ontario, Canada. Participants: The study enrolled had transient For each...
Abstract Aims Patients with coronary artery disease (CAD) and patients peripheral (PAD) are at risk for major adverse cardiovascular events (MACE) limb (MALE). There limited data regarding dietary patterns the of recurrent MACE MALE in CAD PAD patients. We aimed to identify associated and/or PAD. Methods results analysed collected from enrolled into Cardiovascular Outcomes People Using Anticoagulation Strategies (COMPASS) trial, which diet was assessed by a short food frequency questionnaire...